{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:57:35Z","timestamp":1790269055852,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T00:00:00Z","timestamp":1696204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Capital health development research project","award":["2020-2-4082"],"award-info":[{"award-number":["2020-2-4082"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Nonsecretory multiple myeloma (NSMM) is a rare type of multiple myeloma (MM). Few studies have described the clinical features and outcomes of NSMM in novel agents. Additionally, the prognostic characteristics have remained controversial in recent years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>To investigate the clinical and prognostic features of NSMM and explore the prognostic value of involved free light chain (FLC) levels in NSMM patients in the Chinese population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively enrolled 176 newly diagnosed NSMM cases between January 2005 and December 2021 from 19 clinical centers in China. The control group was selected using a 1:4 propensity score matching technique of newly diagnosed secretory MM, with age, sex and diagnosis time as the matching variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The median age of NSMM patients was 60\u00a0years, and 22.6% of patients were classified as ISS stage 3. The ORR of the NSMM patients was 87.4%, and the CR was 65.8%. Compared to the matched secretory MM patients, more NSMM patients achieved CR after first-line treatment (65.8% vs. 36%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.000). The ORR of first-line treatment was not significantly different between NSMM and secretory MM (89.45% vs. 84.7%,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.196). The first-line PFS was 27.5\u00a0m and 23\u00a0m (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.063), and the median OS was 81\u00a0m and 70\u00a0months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.401). However, for CR-achieved NSMM and CR-not-achieved NSMM patients, the median PFS was 37\u00a0m vs. 16\u00a0m (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.021), while the median OS showed no difference (107\u00a0m vs. 87\u00a0m,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.290). In multivariate analysis, the significant factors for PFS were age\u2009\u2265\u200965 and ISS-3. ISS-3 was the only independent prognostic factor of OS. The iFLC\u2009\u2265\u200950\u00a0mg\/L group had a high ORR of 97.3%, and the median PFS and OS were 48\u00a0m and NR, respectively. Compared to the matched secretory MM, the iFLC\u2009\u2265\u200950\u00a0mg\/L group also showed more CR and longer OS (NR vs. 70\u00a0m,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.006) and PFS (48\u00a0m vs. 23\u00a0m,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.003).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results revealed that Chinese NSMM patients are younger and have a higher CR but not superior survival. The subgroup of NSMM patients with iFLC\u2009\u2265\u200950\u00a0mg\/L had better outcomes than secretory MM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-023-11223-4","type":"journal-article","created":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T09:02:14Z","timestamp":1696237334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Outcome and characteristics of nonsecretory multiple myeloma compared with secretory multiple myeloma: a retrospective multicenter study from China"],"prefix":"10.1186","volume":"23","author":[{"given":"Hailu","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangxun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Ping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi-Ke","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,2]]},"reference":[{"issue":"5","key":"11223_CR1","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/ejh.13351","volume":"104","author":"G W\u00e5linder","year":"2020","unstructured":"W\u00e5linder G, et al. Outcome and characteristics of non-measurable myeloma: a cohort study with population-based data from the Swedish Myeloma Registry. Eur J Haematol. 2020;104(5):376\u201382.","journal-title":"Eur J Haematol"},{"key":"11223_CR2","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1038\/bcj.2014.55","volume":"4","author":"J Lu","year":"2014","unstructured":"Lu J, et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J. 2014;4:e239.","journal-title":"Blood Cancer J"},{"issue":"12","key":"11223_CR3","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538\u201348.","journal-title":"Lancet Oncol"},{"issue":"9","key":"11223_CR4","doi-asserted-by":"publisher","first-page":"2900","DOI":"10.1182\/blood.V97.9.2900","volume":"97","author":"M Drayson","year":"2001","unstructured":"Drayson M, et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97(9):2900\u20132.","journal-title":"Blood"},{"issue":"3","key":"11223_CR5","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1038\/sj.bmt.1703818","volume":"31","author":"E Terpos","year":"2003","unstructured":"Terpos E, et al. Autologous stem cell transplantation in multiple myeloma: improved survival in nonsecretory multiple myeloma but lack of influence of age, status at transplant, previous treatment and conditioning regimen. A single-centre experience in 127 patients. Bone Marrow Transplant. 2003;31(3):163\u201370.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"11223_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"RA Kyle","year":"2003","unstructured":"Kyle RA, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78(1):21\u201333.","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"11223_CR7","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1111\/ejh.12478","volume":"95","author":"SS Chawla","year":"2015","unstructured":"Chawla SS, et al. Clinical course and prognosis of non-secretory multiple myeloma. Eur J Haematol. 2015;95(1):57\u201364.","journal-title":"Eur J Haematol"},{"issue":"6","key":"11223_CR8","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00277-020-03984-w","volume":"99","author":"M Migkou","year":"2020","unstructured":"Migkou M, et al. Clinical characteristics and outcomes of oligosecretory and non-secretory multiple myeloma. Ann Hematol. 2020;99(6):1251\u20135.","journal-title":"Ann Hematol"},{"issue":"1","key":"11223_CR9","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.clml.2019.09.624","volume":"20","author":"B Nandakumar","year":"2020","unstructured":"Nandakumar B, et al. Cytogenetic features and clinical outcomes of patients with non-secretory multiple myeloma in the era of novel agent induction therapy. Clin Lymphoma Myeloma Leuk. 2020;20(1):53\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"11223_CR10","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/hon.2900040407","volume":"4","author":"DB Smith","year":"1986","unstructured":"Smith DB, et al. Non-secretory multiple myeloma: a report of 13 cases with a review of the literature. Hematol Oncol. 1986;4(4):307\u201313.","journal-title":"Hematol Oncol"},{"issue":"10","key":"11223_CR11","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1016\/j.bbmt.2008.07.011","volume":"14","author":"S Kumar","year":"2008","unstructured":"Kumar S, et al. Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant. 2008;14(10):1134\u201340.","journal-title":"Biol Blood Marrow Transplant"},{"key":"11223_CR12","doi-asserted-by":"publisher","first-page":"100643","DOI":"10.1016\/j.blre.2019.100643","volume":"41","author":"A Paner","year":"2020","unstructured":"Paner A, Patel P, Dhakal B. The evolving role of translocation t(11;14) in the biology, prognosis, and management of multiple myeloma. Blood Rev. 2020;41:100643.","journal-title":"Blood Rev"},{"key":"11223_CR13","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.clml.2022.01.013","volume":"22","author":"L Gao","year":"2022","unstructured":"Gao L, et al. The Importance of FISH Signal Cut-off Value and Copy Number Variation for 1q21 in Newly Diagnosed Multiple Myeloma: Is it Underestimated? Clin Lymphoma Myeloma Leuk. 2022;22:535\u201344.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"11223_CR14","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328\u201346.","journal-title":"Lancet Oncol"},{"issue":"15","key":"11223_CR15","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1182\/blood-2009-03-201053","volume":"114","author":"JL Harousseau","year":"2009","unstructured":"Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood. 2009;114(15):3139\u201346.","journal-title":"Blood"},{"issue":"4","key":"11223_CR16","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2002-08-2436","volume":"101","author":"H Avet-Loiseau","year":"2003","unstructured":"Avet-Loiseau H, Garand R, Lod\u00e9 L, Harousseau JL, Bataille R, Intergroupe Francophone du My\u00e9lome. Translocation t(11;14)(q13;q32) is the hallmark of IgM, IgE, and nonsecretory multiple myeloma variants. Blood. 2003;101(4):1570\u20131.","journal-title":"Blood"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11223-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-023-11223-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-023-11223-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:06:04Z","timestamp":1700438764000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-023-11223-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,2]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["11223"],"URL":"https:\/\/doi.org\/10.1186\/s12885-023-11223-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-2346555\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,2]]},"assertion":[{"value":"5 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study have been performed in accordance with the Declaration of Helsinki. And it was approved by the IRB of Peking University People\u2019s Hospital. (2022PHB250-001) Due to retrospective nature of the study, the need for written informed consent was waived by the IRB of Peking University People\u2019s Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"930"}}